ADCYAP1 and migraine disorder: One of innovation of this study, that KYNA-a can downregulate both protein and gene expression of preproPACAP and PACAP1–38, suggesting that KYNA-a is a potential new drug in the PACAP-targeted migraine therapy in the future.